Richard J Rodgers
CIK 1313397 · Interim CEO and President · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.14M
Companies
7
Total Filings
56
Lifetime Open-Market Net
$0
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVAX | Director | 47,370 | $7.95 | $376.6K | $0 | 9 | 2026-06-23 |
| ARDX | Director | 439,998 | $4.00 | $1.76M | $0 | 13 | 2026-06-18 |
| Opus Genetics, Inc. (OCUP) Delisted | Director | 343,022 | $1.17 | $401.3K | $0 | 19 | 2026-04-22 |
| SGMT | Director | — | $9.06 | — | $0 | 1 | 2023-07-20 |
| Opus Genetics, Inc. (RNN) Delisted | Director | — | — | — | $0 | 6 | 2019-06-07 |
| TESARO, Inc. (TSRO) Delisted | Executive VP & CFO | 257,141 | — | — | $0 | 2 | 2013-03-08 |
| MGI PHARMA INC (MOGN) Delisted | Sr. VP & Controller | 4,474 | — | — | $0 | 4 | 2008-01-24 |
Recent Filings · Page 3 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-01-12 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +20,822 | $0 | EDGAR |
| 2022-11-01 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2022-10-04 | Opus Genetics, Inc. (OCUP) Delisted | Exer (X) | +3,148 | $0 | EDGAR |
| 2022-07-06 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +23,653 | $0 | EDGAR |
| 2022-06-17 | ARDX | Grant (A) | +132,299 | $0 | EDGAR |
| 2022-06-15 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-04-05 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +4,629 | $0 | EDGAR |
| 2022-01-05 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +4,021 | $0 | EDGAR |
| 2021-10-04 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +2,912 | $0 | EDGAR |
| 2021-07-02 | Opus Genetics, Inc. (OCUP) Delisted | Grant (A) | +2,840 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.